DRUG COSTS
Out of control—or delivering value?
We review some commonly used drug-pricing terms in the U.S. pharmaceutical market, including their calculations and roles in the healthcare industry.
The Centers for Medicare and Medicaid Services announced the list of drugs selected for price negotiation for 2028. We broke down the implications.
Medicare drug price negotiation: With the first cycle where Part B drugs are eligible to be selected, the implications extend far beyond simple price reductions.
To help Medicare Advantage plans navigate significant challenges and opportunities in 2026, we offer insight on six developing issues.
We discuss key insights from the 2026 Medicare Advantage bids that life sciences leaders should consider when planning for the future.
We detail factors in Phase-3 clinical trial design that influence health insurance coverage decisions.
A current perspective for patients with diabetes, hypertension, and hyperlipidemia
Medicare Advantage (MA) and Part D insurers are citing significant financial headwinds in earnings calls and the press. Statutory financial statements provide insights into emerging trends through year-end 2024.
Maximum Fair Price (MFP) Issue Brief 2
Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.
